作者: D. Hoelzer , A. Ganser , O. G. Ottmann , K. Höffken , R. Becher
DOI: 10.1007/978-3-642-74643-7_138
关键词:
摘要: Treatment of patients having myelodysplastic a syndromes (MDS) with approaches such as differentiation induction, single cytostatic agents or supportive care only has, up to now, been rather unsuccessful. Aggressive chemotherapy followed by bone marrow transplantation is suitable for very small proportion patients. Thus, there need new therapeutic alternatives.